Imatinib-AFT Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

imatinib-aft

aft pharmaceuticals ltd - imatinib mesilate 119.47mg equivalent to imatinib 100 mg;   - capsule - 100 mg - active: imatinib mesilate 119.47mg equivalent to imatinib 100 mg   excipient: crospovidone gelatin iron oxide red iron oxide yellow lactose monohydrate magnesium stearate titanium dioxide - treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive chronic myeloid leukaemia (ph+cml). treatment of adult and paediatic patients with ph+cml in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.

Imatinib-AFT Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

imatinib-aft

aft pharmaceuticals ltd - imatinib mesilate 477.88mg equivalent to imatinib 400 mg;   - capsule - 400 mg - active: imatinib mesilate 477.88mg equivalent to imatinib 400 mg   excipient: crospovidone gelatin iron oxide black iron oxide red iron oxide yellow lactose monohydrate magnesium stearate titanium dioxide - treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive chronic myeloid leukaemia (ph+cml). treatment of adult and paediatic patients with ph+cml in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.

TRISENOX Ισραήλ - Αγγλικά - Ministry of Health

trisenox

medison pharma ltd - arsenic trioxide - solution for injection - arsenic trioxide 1 mg/ml - arsenic trioxide - arsenic trioxide - trisenox is indicated for induction of remission, and consolidation in adult patients with:• newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 1000/μl) in combination with all-trans-retinoic acid (atra)• relapsed/refractory acute promyelocytic leukaemia (apl)(previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rar-alpha) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.

ADCETRIS® POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MGVIAL Σιγκαπούρη - Αγγλικά - HSA (Health Sciences Authority)

adcetris® powder for concentrate for solution for infusion 50mgvial

takeda pharmaceuticals (asia pacific) pte. ltd. - brentuximab vedotin - injection, powder, for solution - 50mg/vial - brentuximab vedotin 50mg/vial

NAPROXEN tablet Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

naproxen tablet

nucare pharmaceuticals, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 375 mg - carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen tablets or naproxen sodium tablets. use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals (see warnings: gastrointestinal bleeding, ulceration, and perforation). naproxen as naproxen tablets or naproxen sodium tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis for the relief of the signs and symptoms of osteoarthritis for the relief of the signs and symptoms of ankylosing spondylitis for the relief of the signs and symptoms of juvenile arthritis - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as napr

NAPROXEN SODIUM- naproxen sodium tablet Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

naproxen sodium- naproxen sodium tablet

nucare pharmaceuticals, inc. - naproxen sodium (unii: 9tn87s3a3c) (naproxen - unii:57y76r9atq) - naproxen sodium 550 mg - carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen tablets or naproxen sodium tablets. use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals (see warnings: gastrointestinal bleeding, ulceration, and perforation). naproxen as naproxen tablets or naproxen sodium tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis for the relief of the signs and symptoms of osteoarthritis for the relief of the signs and symptoms of ankylosing spondylitis for the relief of the signs and symptoms of juvenile arthritis - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as naproxen tablets or naproxen so

NAPROXEN tablet Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

naproxen tablet

nucare pharmaceuticals, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen tablets or naproxen sodium tablets. use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals (see warnings: gastrointestinal bleeding, ulceration, and perforation). naproxen as naproxen tablets or naproxen sodium tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis for the relief of the signs and symptoms of osteoarthritis for the relief of the signs and symptoms of ankylosing spondylitis for the relief of the signs and symptoms of juvenile arthritis - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as napr

NAPROXEN tablet Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

naproxen tablet

nucare pharmaceuticals, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen tablets or naproxen sodium tablets. use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals (see warnings: gastrointestinal bleeding, ulceration, and perforation). naproxen as naproxen tablets or naproxen sodium tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis for the relief of the signs and symptoms of osteoarthritis for the relief of the signs and symptoms of ankylosing spondylitis for the relief of the signs and symptoms of juvenile arthritis - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as napr

DEMUSTIN 25 MG Ισραήλ - Αγγλικά - Ministry of Health

demustin 25 mg

rafa laboratories ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg/vial - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

DEMUSTIN 25 MG Ισραήλ - Αγγλικά - Ministry of Health

demustin 25 mg

rafa laboratories ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg/vial - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.